Cargando…

Analysis of early death in newly diagnosed acute promyelocytic leukemia patients

The aim of this study was to identify risk factors for early death (ED) in acute promyelocitic leukemia (APL) patients. Clinical records of 49 APL patients who suffered ED were divided into 4 groups: death before treatment or within the first 3 days (immediate death; iED group), death during treatme...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Fang, Wang, Chunli, Yin, Changxin, Jiang, Xuejie, Jiang, Ling, Wang, Zhixiang, Meng, Fanyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5758210/
https://www.ncbi.nlm.nih.gov/pubmed/29390508
http://dx.doi.org/10.1097/MD.0000000000009324
_version_ 1783290965472051200
author Xu, Fang
Wang, Chunli
Yin, Changxin
Jiang, Xuejie
Jiang, Ling
Wang, Zhixiang
Meng, Fanyi
author_facet Xu, Fang
Wang, Chunli
Yin, Changxin
Jiang, Xuejie
Jiang, Ling
Wang, Zhixiang
Meng, Fanyi
author_sort Xu, Fang
collection PubMed
description The aim of this study was to identify risk factors for early death (ED) in acute promyelocitic leukemia (APL) patients. Clinical records of 49 APL patients who suffered ED were divided into 4 groups: death before treatment or within the first 3 days (immediate death; iED group), death during treatment at least 3 days after commencement (ED after treatment), low/intermediate risk, and high-risk groups. White blood cell (WBC) count, high-risk cases, prothrombin time (PT) prolongation, international society on thrombosis and hemostasis (ISTH) scores (P < .05), bleeding (P = .05), and death due to severe hemorrhage (P = .010) were higher in iED group than ED after treatment. And the time from onset to initial hospitalization or death was significantly shorter (P < .05) in iED patients. LDH level (P = .002), PT prolongation (P = .014), and incidence of grades 3 or 4 bleeding (P = .049) were higher in high-risk group than in ED and low/intermediate-risk groups, while the times from onset to the initial hospitalization or death were lower for ED patients in high-risk group (P = .037). We found that different types of EDs have different clinical features. A high WBC count contributes to the occurrence of more ED, which is usually not associated with delay of diagnosis and hospitalization. Current therapeutic strategies to reduce the incidence of ED in these cases are not adequate and will benefit from focused research attention.
format Online
Article
Text
id pubmed-5758210
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-57582102018-01-29 Analysis of early death in newly diagnosed acute promyelocytic leukemia patients Xu, Fang Wang, Chunli Yin, Changxin Jiang, Xuejie Jiang, Ling Wang, Zhixiang Meng, Fanyi Medicine (Baltimore) 4800 The aim of this study was to identify risk factors for early death (ED) in acute promyelocitic leukemia (APL) patients. Clinical records of 49 APL patients who suffered ED were divided into 4 groups: death before treatment or within the first 3 days (immediate death; iED group), death during treatment at least 3 days after commencement (ED after treatment), low/intermediate risk, and high-risk groups. White blood cell (WBC) count, high-risk cases, prothrombin time (PT) prolongation, international society on thrombosis and hemostasis (ISTH) scores (P < .05), bleeding (P = .05), and death due to severe hemorrhage (P = .010) were higher in iED group than ED after treatment. And the time from onset to initial hospitalization or death was significantly shorter (P < .05) in iED patients. LDH level (P = .002), PT prolongation (P = .014), and incidence of grades 3 or 4 bleeding (P = .049) were higher in high-risk group than in ED and low/intermediate-risk groups, while the times from onset to the initial hospitalization or death were lower for ED patients in high-risk group (P = .037). We found that different types of EDs have different clinical features. A high WBC count contributes to the occurrence of more ED, which is usually not associated with delay of diagnosis and hospitalization. Current therapeutic strategies to reduce the incidence of ED in these cases are not adequate and will benefit from focused research attention. Wolters Kluwer Health 2017-12-22 /pmc/articles/PMC5758210/ /pubmed/29390508 http://dx.doi.org/10.1097/MD.0000000000009324 Text en Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nd/4.0 This is an open access article distributed under the Creative Commons Attribution-NoDerivatives License 4.0, which allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author. http://creativecommons.org/licenses/by-nd/4.0
spellingShingle 4800
Xu, Fang
Wang, Chunli
Yin, Changxin
Jiang, Xuejie
Jiang, Ling
Wang, Zhixiang
Meng, Fanyi
Analysis of early death in newly diagnosed acute promyelocytic leukemia patients
title Analysis of early death in newly diagnosed acute promyelocytic leukemia patients
title_full Analysis of early death in newly diagnosed acute promyelocytic leukemia patients
title_fullStr Analysis of early death in newly diagnosed acute promyelocytic leukemia patients
title_full_unstemmed Analysis of early death in newly diagnosed acute promyelocytic leukemia patients
title_short Analysis of early death in newly diagnosed acute promyelocytic leukemia patients
title_sort analysis of early death in newly diagnosed acute promyelocytic leukemia patients
topic 4800
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5758210/
https://www.ncbi.nlm.nih.gov/pubmed/29390508
http://dx.doi.org/10.1097/MD.0000000000009324
work_keys_str_mv AT xufang analysisofearlydeathinnewlydiagnosedacutepromyelocyticleukemiapatients
AT wangchunli analysisofearlydeathinnewlydiagnosedacutepromyelocyticleukemiapatients
AT yinchangxin analysisofearlydeathinnewlydiagnosedacutepromyelocyticleukemiapatients
AT jiangxuejie analysisofearlydeathinnewlydiagnosedacutepromyelocyticleukemiapatients
AT jiangling analysisofearlydeathinnewlydiagnosedacutepromyelocyticleukemiapatients
AT wangzhixiang analysisofearlydeathinnewlydiagnosedacutepromyelocyticleukemiapatients
AT mengfanyi analysisofearlydeathinnewlydiagnosedacutepromyelocyticleukemiapatients